<DOC>
	<DOCNO>NCT00651352</DOCNO>
	<brief_summary>Open label , single dose , four-way crossover healthy smoker . Each subject treat single dose four study treatment randomize sequence .</brief_summary>
	<brief_title>A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Subject either male female 18 55 year age inclusive . Subject BMI within range 1927 kg/m² . [ BMI = Weight ( kg ) ÷ Height ( ) ² ] . Subject admits smoke commerciallyavailable cigarette daily precede 12 month routinely smoke first cigarette within 30 minute upon awaken . Subject good general health ( opinion investigator ) clinically significant relevant abnormality assess medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test result ( hematology , biochemistry urinalysis ) within normal limit . If female , subject childbearing potential practicing reliable method contraception opinion investigator . Subject understand willing , able , likely comply study procedure restriction . Subject demonstrate understand study willingness participate evidence voluntary write informed consent . If female , subject pregnant , positive serum pregnancy test screening , breastfeed . Subject disease condition may interfere oral absorption study drug . 1 . A medical history , opinion investigator , might jeopardize safety subject ( e.g . rheumatoid arthritis , circulatory problem , recent myocardial infarction , cerebrovascular accident within 12 week prior first study session , unstable worsen angina pectoris , Prinzmetal 's angina severe cardiac arrhythmia ) . 2 . A medical history , opinion investigator , might impact validity study result may require pharmacotherapy prevent subject finishing study . 3 . Oral surgery within 4 week dose , dental work extraction within 2 week dose , presence clinically significant ( determined principal investigator ) oral pathology include lesion , sores inflammation . Subject use chew tobacco tobacco product cigarettes within 21 day Visit 1 . Subject abused alcohol substance within two year screen . For purpose study , alcohol abuse define daily use great two drink per day . Subject positive urine drug screen cannabinoids , amphetamine , cocaine , ecstasy , methamphetamine , opiates . Subject positive serum hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) test result . Subject know suspected intolerance hypersensitivity study material closely related compound state ingredient . Subject genetic deficiency inability metabolize aspartame phenylalanine , diagnose phenylketonuria . Subject participate another clinical study receive investigational drug within 30 day first study session previously participate study . Subject donate experienced significant blood loss within 56 day Visit 2 , donate plasma within 7 day Visit 2 , hemoglobin value &lt; 12.0g/dL . Subject treat known enzymealtering agent ( e.g. , barbiturate , phenothiazine , cimetidine , theophylline ) within 30 day prior first study session . Subject use nicotine replacement therapy within 21 day prior first study session . Subject use overthecounter ( OTC ) medication herbal supplement within 48 hour prior administration study treatment . Subject use prescription medication within 14 day prior study session , exclude hormonal contraceptive hormone replacement therapy . Subject member study site staff employee sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>NRT</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Nicotine</keyword>
</DOC>